Bioyond Robotics ('Bioyond') recently declared the successful closing of its A3 round of financing, amassing hundreds of millions of yuan. The financing round was spearheaded by Panlin Capital, with additional investments from Qiming Venture Partners and BioTrack Capital.
Founded in March 2021 and based in Shanghai Zhangjiang Science City, Bioyond's founding team is a powerhouse of talent from the world's top 500 companies in robotics and life sciences. By merging state-of-the-art robotics, precision visual recognition, and avant-garde artificial intelligence, Bioyond crafts groundbreaking, intuitive, and unmanned intelligent automation products and solutions for a variety of labs engaged in scientific research, clinical diagnostics, and chemical applications, setting new benchmarks for industry applications. With its advanced technologies in robotics, automation, and AI, coupled with a profound understanding of life science scenarios, the company has developed a versatile lab robotics platform—LabGenius, a comprehensive lab software platform—LabMind, and a compact intelligent lab application platform—LabMate. These platforms are designed to cater to the intelligent automation needs across different scenarios. Bioyond has successfully executed major projects in critical areas such as drug screening, synthetic biology, cell and gene therapy, genomics research, applied chemistry, and clinical diagnostics. The company's exceptional technical capabilities and efficient project delivery have consistently provided clients with leading-edge intelligent lab automation solutions.
Since its inception, Bioyond has completed multiple rounds of financing, raising hundreds of millions of yuan, primarily allocated to technological R&D, product development and manufacturing, and market expansion. This funding has allowed the company to continuously meet the urgent demands for intelligent automation products and solutions in the biopharmaceutical and related industries. Looking ahead, as standardized products continue to be launched and new application scenarios are explored, Bioyond's technical prowess and product competitiveness are expected to gain further recognition.
Serving as Bioyond's legal advisor, Llinks has leveraged its extensive experience in investment and financing to provide expert legal services for Bioyond's latest round of financing.
Llinks Team:
Partners: Selena She, Colin Shi
Contractual Partner: Aurora Zhang
